Arcutis Biotherapeutics' Q3 revenue jumps to $99.2 mln

Arcutis Biotherapeutics

28/10/2025 12:38

Overview

Arcutis Q3 2025 net product revenue for ZORYVE rises 122% yr/yr to $99.2 mln

Company reports Q3 net income of $7.4 mln, reversing a loss from last year

ZORYVE cream receives FDA approval for atopic dermatitis in children ages 2 to 5

Outlook

Company provides initial 2026 full-year net product sales guidance of $455–$470 mln

Arcutis aims for potential peak ZORYVE sales of $2.6–$3.5 bln per annum

Result Drivers

DEMAND AND LAUNCH - Sequential growth driven by increased demand and launch of ZORYVE foam 0.3% for plaque psoriasis

FDA APPROVAL - FDA approval of ZORYVE cream 0.05% for atopic dermatitis in children expected to boost sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$99.21 mln
Q3 EPS
$0.06
Q3 Net Income
$7.41 mln
Q3 Operating Expenses
$90.69 mln
Q3 Operating Income
$8.52 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $22.50, about 12.7% above its October 27 closing price of $19.64

Press Release: ID:nGNX71n4sS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)